Dark Horse Consulting Group Inc.
Katharine (Katy) Spink is an accomplished leader in the biotechnology sector, currently serving as President & COO, Managing Partner, and Board Director at Dark Horse Consulting Group Inc., a firm specializing in Cell and Gene Therapy product development since January 2018. In addition, Spink holds board positions at MicrofluidX and Single Use Support GmbH and chairs the CMC and Commercialization Committees of the American Society of Gene & Cell Therapy. Previously, Spink was Chief Operating Officer at Asterias Biotherapeutics, where responsibilities included comprehensive program management and business development. With expertise rooted in a Ph.D. in Cancer Biology from Stanford University School of Medicine and extensive experience in various roles at Geron Corporation and McKinsey & Company, Spink has a proven track record in operational leadership, strategic planning, and alliance management within the biotechnology industry.
Previous companies
This person is not in any teams
This person is not in any offices
Dark Horse Consulting Group Inc.
AT DARK HORSE CONSULTING, we work to accelerate cell and gene therapies through our unmatched expertise. Our consulting team has extensive CGT industry experience with knowledge spanning manufacturing, process development, comparability, analytical dev, quant modeling, quality systems, regulatory support, preclinical dev, device dev, program management, facility design and enginnering, market research, and due diligence and business strategy. Many of our consultants also bring experience from adjacent, more mature, sectors, including traditional biologics, small molecules, medical devices, and management consulting. Client requests range from scientific expertise to tactical needs to strategic considerations to business development. We understand the unique challenges faced by Cell and Gene Therapy developers like none other. We apply best practices from across this and other industries to address the needs of our clients, who range from biopharmaceutical companies to tools & tech providers to investment firms.